Document is current
Any future updates will be listed below
-
Authors
Botta, Cirino http://orcid.org/0000-0002-1522-4504
Perez, Cristina http://orcid.org/0000-0003-3586-2666
Larrayoz, Marta http://orcid.org/0000-0001-6097-8244
Puig, Noemi
Cedena, Maria-Teresa http://orcid.org/0000-0001-5851-3720
Termini, Rosalinda
Goicoechea, Ibai http://orcid.org/0000-0002-5329-2225
Rodriguez, Sara http://orcid.org/0000-0001-6509-0447
Zabaleta, Aintzane
Lopez, Aitziber
Sarvide, Sarai
Blanco, Laura
Papetti, Daniele M. http://orcid.org/0000-0002-3574-6027
Nobile, Marco S. http://orcid.org/0000-0002-7692-7203
Besozzi, Daniela http://orcid.org/0000-0001-5532-3059
Gentile, Massimo
Correale, Pierpaolo
Siragusa, Sergio
Oriol, Albert
González-Garcia, Maria Esther
Sureda, Anna
de Arriba, Felipe
Rios Tamayo, Rafael http://orcid.org/0000-0001-8193-1402
Moraleda, Jose-Maria http://orcid.org/0000-0001-9080-1466
Gironella, Mercedes
Hernandez, Miguel T.
Bargay, Joan
Palomera, Luis
Pérez-Montaña, Albert
Goldschmidt, Hartmut http://orcid.org/0000-0003-0961-0035
Avet-Loiseau, Hervé
Roccaro, Aldo http://orcid.org/0000-0002-1872-5128
Orfao, Alberto http://orcid.org/0000-0002-0007-7230
Martinez-Lopez, Joaquin
Rosiñol, Laura http://orcid.org/0000-0002-2534-9239
Lahuerta, Juan-José http://orcid.org/0000-0002-3393-9570
Blade, Joan http://orcid.org/0000-0002-4563-3405
Mateos, Maria-Victoria http://orcid.org/0000-0003-2390-1218
San-Miguel, Jesús F. http://orcid.org/0000-0002-9183-4857
Martinez Climent, Jose-Angel http://orcid.org/0000-0002-7938-3950
Paiva, Bruno http://orcid.org/0000-0003-1977-3815
,
,
- License Information
-
More Information
Article History
Received: 25 November 2022
Accepted: 7 September 2023
First Online: 20 September 2023
Competing interests
: C.B. has served as a member on advisory boards for Amgen, Janssen, Pfizer, Takeda, and Oncopeptides; A.R. has received honoraria from Amgen, Celgene, and Janssen and a research grant from AstraZeneca and the Associazione Italiana per la Ricerca sul Cancro (AIRC): AIRC-IG-24689. H.G. has received speakers bureau honoraria from Academy2, KG, Agentur Hogg Robinson Germany, Amgen, ArtTempi, Beupdated Helbig Consulting and Research AG Schweiz, Bristol Myers Squibb, Celgene, Chop, Chugai, Congress Culture Concept Dr. S. Stocker München, Connectmedia Warschau/Polen, Dr. Hubmann Tumorzentrum München, FomF, GlaxoSmithKline, GWT Forschung und Innovation Dresden, Institut für Versorgungsforschung in der Onkologie GbR, Janssen, Kompetenznetz Maligne Lymphome, MedConcept, Medical Communication, Münchner Leukämie Labor Prof. Haferlach, New Concept Oncology, Novartis, Omnia Med Deutschland, Onko Internetportal DKG-web, Sanofi, STIL Forschungs, and Veranstaltungskonzept Gesundheit Mechernich, has served as a member on advisory boards for Adaptive Biotechnology, Amgen, Bristol Myers Squibb, Celgene, Janssen, Sanofi, and Takeda, and has received research grants and/or materials such as investigational medicinal products from Amgen, Bristol Myers Squibb, Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, John Hopkins University, and Sanofi. A. Oriol participated in advisory boards for Amgen, Celgene and Janssen. M.-V.M. has received honoraria for lectures from or participated in advisory boards for Janssen, Celgene, Amgen, Takeda, AbbVie, Adaptive, GSK, Pharmamar, EDO, and Oncopeptides. L.R. reports honoraria from Janssen, Celgene, Amgen, and Takeda. J.B. reports honoraria for lectures from Janssen, Amgen, Celgene, Takeda, and Oncopeptides. J.-J.L. reports honoraria from and membership on boards of directors or advisory committees with Takeda, Amgen, Celgene, and Janssen. J.F.S.-M. reports consultancy for Bristol-Myers Squibb, Celgene, Novartis, Takeda, Amgen, MSD, Janssen, and Sanofi and membership on a board of directors or advisory committee with Takeda. J.A.M.-C. has received research grants from Roche, Bristol-Myers Squibb-Celgene, and Janssen. B.P. reports honoraria for lectures from and membership on advisory boards with Adaptive, Amgen, Becton Dickinson, Bristol-Myers Squibb-Celgene, Janssen, Merck, Novartis, Roche, Sanofi and Takeda; unrestricted grants from Bristol-Myers Squibb-Celgene, EngMab, Roche, Sanofi, and Takeda; and consultancy for Bristol-Myers Squibb-Celgene, Janssen, Sanofi, and Takeda. The remaining authors declare no competing interests.
